Clinical Trials Logo

Filter by:
NCT ID: NCT05429658 Completed - Clinical trials for Acute Ischemic Stroke

Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System

SUMMITNZ
Start date: September 27, 2019
Phase: N/A
Study type: Interventional

The objective of the study is to evaluate the safety and effectiveness of the Route 92 Medical Reperfusion System when used to aspirate emboli in acute ischemic stroke patients.

NCT ID: NCT05423106 Not yet recruiting - Healthy Clinical Trials

A Single and Multiple Ascending Dose Study of JNJ-64457744

Start date: June 29, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety and tolerability of: single ascending dose (SAD) and multiple ascending dose (MAD) administration of JNJ-64457744, administered to healthy adult participants (Part 1 and Part 3), including a cohort of Asian participants (Part 1); and after single dose administration of JNJ-64457744 to chronic hepatitis B (CHB) participants who are virologically suppressed on nucleos(t)ide analog (NA) treatment (tenofovir disoproxil fumarate [TDF], tenofovir alafenamide [TAF], or entecavir [ETV]) (Part 2).

NCT ID: NCT05418101 Recruiting - Autoimmune Diseases Clinical Trials

A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)

Start date: April 28, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and in participants with autoimmune disease(s).

NCT ID: NCT05414981 Recruiting - Chronic Hepatitis B Clinical Trials

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection

Start date: June 2022
Phase: Phase 1
Study type: Interventional

This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-H3733 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50 subjects, randomized 8:2 to receive ABI-H3733 or placebo.

NCT ID: NCT05409066 Not yet recruiting - Clinical trials for Follicular Lymphoma (FL)

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

EPCORE FL-1
Start date: September 7, 2022
Phase: Phase 3
Study type: Interventional

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 642 adult participants with R/R FL will be enrolled in approximately 300 sites across the world. Participants will receive R2 (intravenous infusion of rituximab up to 5 cycles and oral capsules of lenalidomide for up to 12 cycles) alone or in combination with subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

NCT ID: NCT05398029 Not yet recruiting - Clinical trials for Hypercholesterolemia

A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease

Start date: July 2022
Phase: Phase 1
Study type: Interventional

VT-1001 is an open-label, phase 1b, single-ascending dose study that will evaluate the safety of VERVE-101 administered to patients with heterozygous familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease (ASCVD), and uncontrolled hypercholesterolemia. VERVE-101 uses base-editing technology designed to disrupt the expression of the PCSK9 gene in the liver and lower circulating PCSK9 and LDL-C in patients with established ASCVD due to HeFH. This study is designed to determine the safety and pharmacodynamic profile of VERVE-101 in this patient population.

NCT ID: NCT05381909 Not yet recruiting - Solid Tumor, Adult Clinical Trials

Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors

Start date: June 8, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, and non-randomized Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-24714 as monotherapy and in combination with chemotherapy in participants with advanced or metastatic solid tumors.

NCT ID: NCT05375396 Recruiting - Clinical trials for Microbial Colonization

Microbial Colonization of Dairy Free Oral Probiotics

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the colonization efficacy of probiotic lozenges containing dairy and dairy free probiotic Streptococcus salivarius M18, in healthy adults

NCT ID: NCT05375383 Recruiting - Clinical trials for Microbial Colonization

Microbial Colonization of Oral Probiotics

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the colonization efficacy of probiotic lozenges and powders containing specific prebiotics in healthy adults

NCT ID: NCT05374070 Recruiting - Clinical trials for Lower Respiratory Tract Infection

Antiviral Activity of Oral Probiotics

Start date: May 23, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to test saliva samples obtained from healthy human participants for anti-viral activity after they have consumed S. salivarius probiotic in a powder format.